| P2093 | author name string | Nicolas Penel | |
| | Arnauld Villers | |
| | David Pasquier | |
| | Philippe Puech | |
| | Clio Baillet | |
| | Anthony Turpin | |
| | Jonathan Olivier | |
| | Edwina Girard | |
| P2860 | cites work | Diagnostic accuracy of multiparametric magnetic resonance imaging in detecting extracapsular extension in intermediate and high - risk prostate cancer | Q88145478 |
| | Metastatic Prostate Cancer | Q88472881 |
| | [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study | Q88645082 |
| | Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer | Q89017227 |
| | Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer | Q89290059 |
| | Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer | Q92169311 |
| | 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial | Q92375760 |
| | Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Pat | Q93159970 |
| | Diagnostic Performance of Diffusion-weighted Magnetic Resonance Imaging in Bone Malignancy: Evidence From a Meta-Analysis | Q26777520 |
| | Imaging of bone metastasis: An update | Q26784751 |
| | EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer | Q38945683 |
| | Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT. | Q38970113 |
| | Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy | Q39143177 |
| | Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer | Q41038146 |
| | 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry | Q41576374 |
| | Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients | Q41634353 |
| | Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer | Q41683899 |
| | Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent | Q41829682 |
| | FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. | Q42117913 |
| | 11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer. | Q42371661 |
| | Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer | Q42379563 |
| | PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy | Q43122510 |
| | Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. | Q44114886 |
| | Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry | Q44942846 |
| | Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 | Q45957143 |
| | 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms | Q46612087 |
| | PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. | Q46823336 |
| | Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients | Q47133990 |
| | Seminal vesicle invasion on multi-parametric magnetic resonance imaging: Correlation with histopathology | Q47246955 |
| | Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital | Q47386024 |
| | Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. | Q48089415 |
| | (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. | Q48139886 |
| | Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions | Q48189196 |
| | Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary ana | Q48898788 |
| | The use of PET/CT in prostate cancer | Q49919217 |
| | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | Q50053735 |
| | 18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study | Q50099352 |
| | Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology | Q28071705 |
| | PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2 | Q29037908 |
| | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 |
| | Alpha emitter radium-223 and survival in metastatic prostate cancer | Q29617472 |
| | Abiraterone and increased survival in metastatic prostate cancer | Q29617512 |
| | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 |
| | Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Q30277291 |
| | Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer | Q30278902 |
| | METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. | Q31108842 |
| | Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer | Q33711641 |
| | Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients | Q33841484 |
| | Noninvasive detection of clinically occult lymph-node metastases in prostate cancer | Q34207093 |
| | Enzalutamide in metastatic prostate cancer before chemotherapy | Q34422206 |
| | 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT. | Q34479713 |
| | Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone | Q35068005 |
| | Baseline staging of newly diagnosed prostate cancer: a summary of the literature | Q35764382 |
| | Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. | Q35879087 |
| | Developing imaging strategies for castration resistant prostate cancer | Q36152211 |
| | Imaging prostate cancer: a multidisciplinary perspective | Q36773229 |
| | The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis | Q37104080 |
| | Prostate cancer: role of SPECT and PET in imaging bone metastases | Q37607846 |
| | Imaging of prostate cancer local recurrences: why and how? | Q37634367 |
| | 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients | Q37696901 |
| | Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations | Q37786892 |
| | [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. | Q38004182 |
| | Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. | Q38084588 |
| | Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis | Q38212848 |
| | Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. | Q38241465 |
| | Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography | Q38242555 |
| | Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT. | Q38564109 |
| | Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment | Q38680652 |
| | Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. | Q38706310 |
| | Current use of PSMA-PET in prostate cancer management | Q38744524 |
| | Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer | Q38746278 |
| | Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer. | Q38802235 |
| | Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. | Q38920663 |
| | 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. | Q50556005 |
| | Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. | Q50613922 |
| | 18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy. | Q50635500 |
| | Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer. | Q50953102 |
| | Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. | Q51081679 |
| | Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer. | Q52982270 |
| | (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. | Q52984458 |
| | Evaluation of suspected soft tissue lesion in the prostate bed after radical prostatectomy using 3T multiparametric magnetic resonance imaging. | Q53034304 |
| | Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. | Q53083003 |
| | Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. | Q53114228 |
| | Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. | Q53166225 |
| | Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. | Q53194256 |
| | Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. | Q53208097 |
| | Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. | Q53470024 |
| | Interpretation of 11C-choline PET/CT for the diagnosis of local relapse in radically treated prostate cancer | Q56961941 |
| | Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? | Q56973144 |
| | Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and M | Q57105534 |
| | Imaging of distant metastases of prostate cancer | Q57105949 |
| | Accuracy of Multiparametric MRI for Prostate Cancer Detection: A Meta-Analysis | Q57253236 |
| | Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group | Q57299101 |
| | Management of non-metastatic castrate-resistant prostate cancer: A systematic review | Q57299986 |
| | Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT | Q57661498 |
| | The Value of a Baseline Bone Scan in Patients With Newly Diagnosed Prostate Cancer | Q57694312 |
| | Comparative diagnostic value and therapeutic relevance of magnetic resonance imaging and bone marrow scintigraphy in patients with metastatic solid tumors of the axial skeleton | Q57991254 |
| | Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences | Q58564104 |
| | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 |
| | Consensus on molecular imaging and theranostics in prostate cancer | Q64030381 |
| | Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases | Q81834340 |
| | Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging | Q84420848 |
| | Assessing response in bone metastases in prostate cancer with diffusion weighted MRI | Q84459087 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 55 | |
| P577 | publication date | 2020-01-31 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Imaging for Metastasis in Prostate Cancer: A Review of the Literature | |
| P478 | volume | 10 | |